Indivior to pay $600 million to resolve U.S. opioid treatment marketing claims

July 24 (Reuters) - Indivior Plc on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

The company said it had reached the agreement with the U.S. Justice Department, the Federal Trade Commission and U.S. state attorneys general and will make the payments over a period of seven years. (Reporting by Nate Raymond in Boston; editing by Jonathan Oatis) (( and Twitter @nateraymond; 617-856-1312; Reuters Messaging: Keywords: USA INDIVIOR/SETTLEMENT (URGENT)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.